
浏览全部资源
扫码关注微信
1.河北中医学院,石家庄 050200
2.河北省中医院,石家庄 050011
高飞,在读博士,从事中西医结合肾病研究,E-mail:595363137@qq.com
檀金川,教授,博士生导师,从事中西医结合肾病研究,E-mail:1955981973@qq.com
收稿日期:2020-05-14,
网络出版日期:2020-08-13,
纸质出版日期:2020-10-20
移动端阅览
高飞,王泽泽,杨冰等.加味升降散对膜性肾病大鼠PI3K/Akt/mTOR信号通路及自噬的影响[J].中国实验方剂学杂志,2020,26(20):25-31.
GAO Fei,WANG Ze-ze,YANG Bing,et al.Effect of Modified Shengjiangsan Influences on PI3K/Akt/mTOR Signaling Pathway and Autophagy in Rats with Membranous Nephropathy[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(20):25-31.
高飞,王泽泽,杨冰等.加味升降散对膜性肾病大鼠PI3K/Akt/mTOR信号通路及自噬的影响[J].中国实验方剂学杂志,2020,26(20):25-31. DOI: 10.13422/j.cnki.syfjx.20202040.
GAO Fei,WANG Ze-ze,YANG Bing,et al.Effect of Modified Shengjiangsan Influences on PI3K/Akt/mTOR Signaling Pathway and Autophagy in Rats with Membranous Nephropathy[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(20):25-31. DOI: 10.13422/j.cnki.syfjx.20202040.
目的
2
探讨加味升降散对膜性肾病(MN)大鼠的干预作用及相关作用机制。
方法
2
采用大鼠尾静脉注射阳离子化牛血清白蛋白(C-BSA)的方法建立MN大鼠模型。设正常组、模型组、加味升降散组(27.3 g·kg
-1
)和贝那普利组(10 mg·kg
-1
),分别给予相应剂量药物灌胃,每日1次,连续干预4周。给药结束后检测大鼠24 h尿蛋白(UTP)水平,血清总胆固醇(TC),甘油三酯(TG),总蛋白(TP),白蛋白(Alb),肌酐(SCr),尿素氮(BUN)水平;马松(Masson)染色、碘酸六胺银(PASM)染色及透射电镜观察大鼠肾脏病理学变化;免疫荧光观察大鼠肾脏免疫球蛋白(Ig)G沉积;蛋白免疫印迹法(Western blot)检测磷脂酰肌醇-3激酶/蛋白激酶B/雷帕霉素靶蛋白(PI3K/Akt/mTOR)信号通路相关分子及自噬相关指标LC3和Beclin1的表达水平。
结果
2
与正常组比较,模型组大鼠UTP,血清中TC,TG水平均升高,TP,Alb水平明显降低(
P
<
0.05);肾小球增大,基底膜出现不同程度的增厚和空泡变性,嗜复红蛋白沉积,肾小球毛细血管袢IgG弥漫性沉积,上皮下可见大小不等的电子致密物沉积,足细胞足突广泛融合;磷酸化(p)-PI3K,p-Akt和p-mTOR蛋白表达均明显增加(
P
<
0.05),自噬标志蛋白LC3和Beclin1蛋白表达量均明显下降(
P
<
0.05);与模型组比较,加味升降散组和贝那普利组大鼠UTP,血清中TC,TG水平均有不同程度的下降,TP,Alb水平有不同程度的升高(
P
<
0.05);大鼠肾组织病理损伤均有所减轻;p-PI3K,p-Akt和p-mTOR蛋白表达量明显下降(
P
<
0.05);自噬标志蛋白LC3和Beclin1蛋白表达量明显升高(
P
<
0.05)。
结论
2
加味升降散可通过减少尿蛋白,减轻肾脏病理损伤,延缓疾病进展,其作用与抑制PI3K/Akt/mTOR信号通路和激活肾脏自噬有关。
Objective
2
To explore the intervention effect of modified Shengjiangsan in rats with membranous nephropathy (MN) and its related mechanism.
Method
2
Rats were injected with cationized bovine serum Albumin (C-BSA) in the tail vein to establish a rat model of membranous nephropathy. The normal group
model group
modified Shengjiangsan group (27.3 g·kg
-1
) and benazepril group (10 mg·kg
-1
) were established in this study. Each group was given corresponding dosage of the drug once a day for 4 weeks of continuous intervention. After the administration
the levels of 24-hour urine protein (UTP)
total cholesterol (TC)
triglyceride (TG)
total protein (TP)
Albumin (Alb)
creatinine (SCr)
urea nitrogen (BUN) level was detected. we observed the pathological changes of rat kidneys by the technology of Masson staining
silver hexylamine iodate (PASM) staining and transmission electron microscopy. immunofluorescence technology was used to detect immunoglobulin (Ig)G deposition in rat kidneys. Western blot was used to detect the expression levels of key proteins in phosphatidylinositol 3-kinase/proline protein kinase B/rapamycin target protein (PI3K/Akt/mTOR) signaling pathway and autophagy marker proteins LC3 and Beclin1.
Result
2
Compared with normal group
the UTP
serum TC and TG levels were significantly increased
TP and Alb levels were significantly reduced in model group(
P
<
0.05). We detected the kidney pathological changes include of glomerulus enlargement
basement membrane thickening
vacuolar degeneration
pheotropin deposition
glomerular capillary loop IgG diffuse deposition
electron dense deposits of varying sizes and podocytes under the epithelium extensive integration of foot processes, the expression of p-PI3K
p-Akt and p-mTOR protein was significantly increased (
P
<
0.05). The expression of autophagy marker proteins LC3 and Beclin1 protein decreased significantly(
P
<
0.05). Compared with model group
the UTP
serum TC and TG levels were decreased in the benazepril group and modified Shengjiangsan group
and the TP and Alb levels were increased (
P
<
0.05), the histopathological changes of rat kidney were all reduced, the expression of p-PI3K
p-Akt and p-mTOR protein was significantly reduced(
P
<
0.05), autophagy marker proteins LC3 and Beclin1 protein expression were significantly increased.
Conclusion
2
Modified Shengjiangsan can reduce urinary protein
reduce kidney pathological damage and delay disease progression
which is related to its inhibition of PI3K/Akt/mTOR signaling pathway and activation of renal autophagy.
向玲 , 邓跃毅 , 刘旺意 , 等 . 邓跃毅教授活血化瘀法治疗膜性肾病经验荟萃 [J]. 中国中西医结合肾病杂志 , 2019 , 20 ( 3 ): 189 - 191 .
CATTRAN D C , BRENCHLEY P E . Membranous nephropathy:integrating basic science into improved clinical management [J]. Kidney Int , 2017 , 91 ( 3 ): 566 - 574 .
TIAN R , WANG L , CHEN A , et al . Sanqi oral solution ameliorates renal damage and restores podocyte injury in experimental membranous nephropathy via suppression of NF- κ B [J]. Biomed Pharmacother , 2019 , 115 : 1 - 8 .
XU X , WANG G , CHEN N , et al . Long-term exposure to air pollution and increased risk of membranous nephropathy in China [J]. J Am Soc Nephrol , 2016 , 27 ( 12 ): 3739 - 3746 .
MCQUARRIE E P , STIRLING C M , GEDDES C C . Idiopathic membranous nephropathy and nephrotic syndrome:outcome in the era of evidence-based therapy [J]. Nephrol Dial Transpl , 2012 , 27 ( 1 ): 235 - 242 .
BECK L , BOMBACK A S , CHOI M J , et al . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [J]. Am J Kidney Dis , 2013 , 62 ( 3 ): 403 - 441 .
WU L , FENG Z , CUI S , et al . Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway,resulting in reduced podocyte injury [J]. PLoS One , 2013 , 8 ( 5 ): 1 - 10 .
LIANG S , JIN J , GONG J , et al . How many podocyte autophagosomes are there in immunoglobulin A nephropathy and idiopathic membranous nephropathy [J]. Int Urol Nephrol , 2016 , 48 ( 12 ): 1 - 6 .
JIN J , HU K , YE M , et al . Rapamycin reduces podocyte apoptosis and is involved in autophagy and mTOR/P70S6K/4EBP1 signaling [J]. Cell Physiol Biochem , 2018 , 48 ( 2 ): 765 - 772 .
JIN J , ZHAN H , LIN B , et al . Association of podocyte autophagosome numbers with idiopathic membranous nephropathy and secondary membranous nephropathy [J]. Int Urol Nephrol , 2017 , 49 ( 6 ): 1025 - 1031 .
SAXTON R A , SABATINI D M . mTOR signaling in growth,metabolism,and disease [J]. Cell , 2017 , 168 ( 6 ): 960 - 976 .
林劲 , 欧阳辉 , 梁春玲 , 等 . 白芍总苷对膜性肾病大鼠肾脏保护作用及自噬的影响 [J]. 中药新药与临床药理 , 2019 , 30 ( 9 ): 1025 - 1031 .
杜昕 , 刘明 , 檀金川 . 加味升降散治疗膜性肾病的临床观察 [J]. 中国老年学杂志 , 2019 , 39 ( 10 ): 115 - 117 .
刘欣 . 加味升降散对膜性肾病大鼠的肾保护作用及对肾组织CXCL16、FcRn表达的影响 [D]. 石家庄 : 河北医科大学 , 2017 .
BORDER W A , WARD H J , KAMIL E S , et al . Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen [J]. J Clin Invest , 1982 , 69 ( 2 ): 451 - 461 .
徐叔云 , 卞如濂 , 陈修 . 药理实验方法学 [M]. 北京 : 人民卫生出版社 , 2003 : 202 - 203 .
骆琳 , 刘建华 , 吴丽娜 . 特发性膜性肾病预后影响因素的研究进展 [J]. 中华肾脏病杂志 , 2019 , 35 ( 1 ): 70 - 76 .
LIN T , WU V C , WANG C . Autophagy in chronic kidney diseases [J]. Cells , 2019 , 8 ( 1 ): 1 - 20 .
CHOI M E . Autophagy in kidney disease [J]. Annu Rev Physiol , 2020 , 82 ( 1 ): 297 - 322 .
YANG D , LIVINGSTON M J , LIU Z , et al . Autophagy in diabetic kidney disease:regulation,pathological role and therapeutic potential [J]. Cell Mol Life Sci , 2018 , 75 ( 4 ): 669 - 688 .
张筠 , 丁婷 , 唐东兴 , 等 . 雷公藤多苷对糖尿病肾病大鼠肾脏细胞自噬的影响及相关机制 [J]. 解剖学报 , 2020 , 51 ( 3 ): 373 - 377 .
LAHIRI V , HAWKINS W D , KLIONSKY D J . Watch what you (Self-) eat: autophagic mechanisms that modulate metabolism [J]. Cell Metab , 2019 , 29 ( 4 ): 803 - 826 .
JIN J , ZHAN H , LIN B , et al . Association of podocyte autophagosome numbers with idiopathic membranous nephropathy and secondary membranous nephropathy [J]. Int Urol Nephrol , 2017 , 49 ( 6 ): 1025 - 1031 .
鲍丽 , 么冬爱 . 足细胞自噬在膜性肾病经典动物模型中的作用及其激活可能的细胞内机制研究 [J]. 中国煤炭工业医学杂志 , 2019 , 22 ( 3 ): 291 - 295 .
杨凤杰 . 自噬保护被动Heymann肾炎大鼠足细胞的机制研究 [D]. 武汉 : 华中科技大学 , 2014 .
张新颖 , 毛景东 , 杨晓燕 , 等 . AMPK/mTOR信号通路的研究进展 [J]. 微生物学杂志 , 2019 , 39 ( 3 ): 109 - 116 .
舒婷 , 万福生 . PI3K/Akt/mTOR信号通路与自噬及肿瘤的关系 [J]. 中国生物化学与分子生物学报 , 2016 , 32 ( 11 ): 1192 - 1196 .
0
浏览量
17
下载量
6
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621